Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...

Protein S is believed to act as a cofactor (helper) to tissue factor pathway inhibitor (TFPI) and other factors controlling clotting. Protein S by itself doesn't prevent clot formation.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Alhemo is a biologic medicine that blocks a protein called tissue factor pathway inhibitor (TFPI). This substance is normally made by your body and prevents blood from clotting.

Marstacimab targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulation protein that functions to prevent the formation of blood clots and restore hemostasis ...

Hympavzi targets the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulation protein. In developing the treatment, Pfizer trailed Novo Nordisk’s investigational TFPI ...

Tissue factor pathway inhibitor-2 reduces interstitial collagenase degradation of triple-helical collagen and may be of use in the treatment of atherosclerosis. Login. Subscribe. News; Magazines. An ...

TFPI has recently been evaluated in a large phase 3 clinical trial. The tifacogin (recombinant human TFPI) multicenter trial (OPTIMIST), which involved >2,000 patients, ...

FDA today approved marstacimab, an anti-tissue factor pathway inhibitor (anti-TFPI) to prevent or reduce bleeding episodes in patients with hemophilia A and B. Marstacimab, to be sold as Hympavzi ...